Tags

Type your tag names separated by a space and hit enter

Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
Pharmacology. 2003 Nov; 69(3):158-63.P

Abstract

The CB1/CB2 receptor agonist WIN 55212-2 (0.75 mg/kg, i.v.) caused a significant reduction in neurogenic plasma extravasation induced by electrical stimulation of the saphenous nerve in anesthetized rats; WIN 55212-2 at 2.5-10 mg/kg, s.c., also produced a significant reduction in the carrageenan-induced paw edema in conscious rats. The selective CB1 antagonist SR 141716A (0.075-0.75 mg/kg i.v.) antagonized the WIN 55212-2 effects in the plasma extravasation model and antagonized the WIN 55212-2 (2.5 mg/kg, s.c.)-induced decreases in rectal temperature and increases in tail-flick latencies. However, SR 141716A (10 mg/kg, p.o.) failed to antagonize the effects of Win 55212-2 (2.5 mg/kg, s.c.) in the carrageenan model, suggesting that cannabinoid receptors found in the periphery may be able to modulate inflammatory processes in rats.

Authors+Show Affiliations

GlaxoSmithKline SpA, Verona, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

14512703

Citation

Pozzi, Ottorino, et al. "Antagonism Between the Anti-inflammatory Activity of the Cannabinoid WIN 55212-2 and SR 141716A." Pharmacology, vol. 69, no. 3, 2003, pp. 158-63.
Pozzi O, Misiano P, Clark GD, et al. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. Pharmacology. 2003;69(3):158-63.
Pozzi, O., Misiano, P., Clark, G. D., & Visentin, L. (2003). Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. Pharmacology, 69(3), 158-63.
Pozzi O, et al. Antagonism Between the Anti-inflammatory Activity of the Cannabinoid WIN 55212-2 and SR 141716A. Pharmacology. 2003;69(3):158-63. PubMed PMID: 14512703.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. AU - Pozzi,Ottorino, AU - Misiano,Paola, AU - Clark,Geoffrey D, AU - Visentin,Luciano, PY - 2002/11/28/received PY - 2003/05/22/accepted PY - 2003/9/27/pubmed PY - 2004/2/19/medline PY - 2003/9/27/entrez SP - 158 EP - 63 JF - Pharmacology JO - Pharmacology VL - 69 IS - 3 N2 - The CB1/CB2 receptor agonist WIN 55212-2 (0.75 mg/kg, i.v.) caused a significant reduction in neurogenic plasma extravasation induced by electrical stimulation of the saphenous nerve in anesthetized rats; WIN 55212-2 at 2.5-10 mg/kg, s.c., also produced a significant reduction in the carrageenan-induced paw edema in conscious rats. The selective CB1 antagonist SR 141716A (0.075-0.75 mg/kg i.v.) antagonized the WIN 55212-2 effects in the plasma extravasation model and antagonized the WIN 55212-2 (2.5 mg/kg, s.c.)-induced decreases in rectal temperature and increases in tail-flick latencies. However, SR 141716A (10 mg/kg, p.o.) failed to antagonize the effects of Win 55212-2 (2.5 mg/kg, s.c.) in the carrageenan model, suggesting that cannabinoid receptors found in the periphery may be able to modulate inflammatory processes in rats. SN - 0031-7012 UR - https://www.unboundmedicine.com/medline/citation/14512703/Antagonism_between_the_anti_inflammatory_activity_of_the_cannabinoid_WIN_55212_2_and_SR_141716A_ L2 - https://www.karger.com?DOI=10.1159/000072669 DB - PRIME DP - Unbound Medicine ER -